Radiotherapy is potentially an important salvage strategy post‐chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post‐CART progression (SRT). Most received SRT for first post‐CART relapse (71%) to sites previously PET‐avid pre‐CART (79%). Median overall survival (OS) post‐SRT was 10 months. Post‐SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P  = 0·001) and OS (P  = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

中文翻译：

---

CD19嵌合抗原受体（CAR）T细胞治疗后复发/难治性非霍奇金淋巴瘤使用挽救性放疗的早期经验。

放射疗法可能是嵌合抗原受体T细胞疗法（CART）后的一项重要挽救策略，但数据有限。我们回顾了14例接受CART后加急放疗治疗的患者。多数接受首次CART复发的SRT（71％）到先前PET-avid进行CART的部位（79％）。SRT后的总生存期（OS）中位数为10个月。SRT后， 与晚期复发相比，六次局部复发实现了100％的响应（3 =完全，3 =部分），与随后的复发（P  = 0·001）和OS（P = 0·004）的自由度得到了提高。三个被移植到同种异体移植中。经过分析，所有患者都还活着。SRT具有多种用途，可以与新型药物或移植药物整合以尝试持久缓解。